Medicine
Ekterly 300 mg tablet
Ekterly 300 mg tablet is a prescription medicine containing Sebetralstat for oral use, marketed by KalVista Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F). Excursions permitted between 15°C and…
Key facts
- Active ingredient (INN)
- Sebetralstat
- Brand
- Ekterly
- Strength
- 300 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 4 blister pack, 2 blister pack
- Marketing authorisation holder
- KalVista Pharmaceuticals
- Manufacturer
- KalVista Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F). Excursions permitted between 15°C and 30°C (59°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- B06AC08 Sebetralstat
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 3 July 2025
- Identifiers
- RxCUI 2717949, 2717955DailyMed set ID 1d145e2f-8e7e-2e90-e063-6294a90a4449NDC 82928-300Application NDA219301
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 4 blister pack in 1 carton / 1 tablet in 1 blister pack | 82928-300-04 | KalVista Pharmaceuticals | 3 July 2025 |
| 2 blister pack in 1 carton / 2 tablet in 1 blister pack | 82928-300-05 | KalVista Pharmaceuticals | 1 July 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Sebetralstat is a plasma kallikrein inhibitor indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. It is available as tablets for oral use. MedsAcross supplies Sebetralstat for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about SebetralstatFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- EKTERLY prescribing information (KalVista Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Ekterly: European public assessment report (EPAR) · European Medicines Agency
Need Ekterly 300 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.